Trials / Completed
CompletedNCT00858572
STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders
A Phase 1 Study of the HSP90 Inhibitor, STA-9090, Administered Twice Weekly in Subjects With Hematologic Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Synta Pharmaceuticals Corp. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to characterize the safety and efficacy of STA-9090 (ganetespib) in subjects with hematologic malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | STA-9090 (ganetespib) | Chemotherapy agent |
Timeline
- Start date
- 2009-03-01
- Primary completion
- 2011-05-01
- Completion
- 2013-02-01
- First posted
- 2009-03-10
- Last updated
- 2014-09-18
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00858572. Inclusion in this directory is not an endorsement.